This patent covers a device that can be implanted so as to protect the cells inside the device from immune mediated rejection. This is particularly useful for stem cell therapy and therapy with cells that are differentiated from stem cells because it would allow for the use of one cell source in all people.
The device is also useful for transplantation of islet cells that are xenogeneic to the host.
This patent is interesting in light of work by companies such as Diabcell PTY Ltd. (US Patent 7,122,177) and Sernova Corp who are using xenogeneic islets in various types of immune evasion devices.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.